Cost Components of Treatment Protocols of Haemophilia Patients with Inhibitors Using Bypassing Agents in Iran Cost Components of Treatment Protocols of Haemophilia Patients
Iranian Journal of Pharmaceutical Sciences,
Vol. 12 No. 2 (2016),
1 April 2016
,
Page 85-90
https://doi.org/10.22037/ijps.v12.40780
Abstract
Bypassing agents are the most commonly used medicines for the treatment of hemophilia patients with inhibitors. The aim of this study is to identify the cost components of management of bleeding vents in hemophilia patients with inhibitors in Iran.This study is a cross-sectional study using a bottom-up approach to determine the cost components of treatment of hemophilia patients with inhibitors via ascertaining of all direct medical and non-medical costs.The evaluatiion of cost components of 20 patients with 40 episodes of bleeding showed that the price of medicines used is responsible for more than 96% and 97% of costs in treatment of hemophilia patients using FEIBA® and AryoSeven, respectively. The results of this study showed that cost of treating one bleeding episode in hemophilia A patients with high antibody titer using FEIBA is 376 USD compared to 857.3 USD for AryoSeven®.Despite the small number of hemophilia patients with inhibitor in Iran, due to high cost of treating these patients, it is very important to choose the cost-effective treatment protocol for the treatment of these patients.
- bypassing agents
- cost components
- hemophilia
- inhibitor.
How to Cite
References
[2] Pokras SM, Petrilla AA, Weatherall J, Lee WC.The economics of inpatient on-demand treatment for hemophilia with high-responding inhibitors: at US retrospective data analysis. Hemophilia 2012;18:284-290.
[3] Stephens JM, Joshi AV, Sumner M , Botteman MF. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors. Expert Opin. Pharmacother. (2007) 8(8):1127-1136.
[4] Faranoush M , Abolghasemi H, Toogeh Gh, Karimi M, Eshghi P, Managhchi M, et al. A Comparison Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Congenital Factor VII Deficiency. CLIN APPL THROMB HEMOST 1076029614522545, first published on March 19, 2014.
[5] AryoSevenTM [package insert]. AryoGen Biopharma, Tehran,Iran; February 2013.
[6] You CW, Lee SY, Park SK. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in hemophilia patients with inhibitors in Korea. Hemophilia. 2009;15:217–226.
[7] Tolpin HG, Bentkover JD. Economic costs of illness: decision making applications and Practical considerations. In: Scheffler, R, Rossiter L, editors. Advances in health economics and Health service resources. Greenwich (CT): JAI Press, 1983.
[8] Bonnet PO, Yoon BS, Wong WY, Boswell K , Ewenstein BM. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa in hemophilia patients with inhibitors undergoing major orthopedic surgeries. Haemophilia 2009; 15: 1083–1089.
[9] Goudemand J. "Hemophilia. Treatment of patients with inhibitors: cost issues”, Haematology Department, Centre Hospitalier regional et Universitaire, Lille, France, 1999 Nov; 5 (6): 397-401.
[10] Ozelo MC, Villaca PR, De Almeida JOSC, Bueno TMF, DE Miranda PAP, Hart WM et al. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil. Haemophilia 2007; 13: 462–469.
[11] Escobar MA. Health economics in haemophilia: a review from the clinician’s perspective. Haemophilia 2010;16:29-34.
[12] Golestani M , Eshghi P, Rasekh HR, Cheraghali AM , Salamzadeh J Imani A. Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors. Iran Red Crescent MED J. 2014 December; 16(12): e24551.
- Abstract Viewed: 322 times
- IJPS_Volume 12_Issue 2_Pages 85-90 Downloaded: 179 times